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DOI 10.1186/s40478-017-0462-4RESEARCH Open AccessComplement regulator CD59 prevents
peripheral organ injury in rats made
seropositive for neuromyelitis optica
immunoglobulin G
Xiaoming Yao and Alan S. Verkman*Abstract
Pathogenesis in aquaporin-4 immunoglobulin G (AQP4-IgG) seropositive neuromyelitis optica spectrum disorders
(herein called NMO) involves complement-dependent cytotoxicity initiated by AQP4-IgG binding to astrocyte AQP4.
We recently reported that rats lacking complement inhibitor protein CD59 were highly susceptible to development
of NMO pathology in brain and spinal cord following direct AQP4-IgG administration (Yao and Verkman, Acta
Neuropath Commun 2017, 5:15). Here, we report evidence that CD59 is responsible for protection of peripheral,
AQP4-expressing tissues in seropositive NMO. Rats made seropositive by intraperitoneal injection of AQP4-IgG
developed marked weakness by 24 h and died soon thereafter. Serum creatine phosphokinase at 24 h was
>900-fold greater in seropositive CD59−/− rats than in seropositive CD59+/+ (or control) rats. AQP4-expressing
cells in skeletal muscle and kidney, but not in stomach, of seropositive CD59−/− rats showed injury with deposition of
AQP4-IgG and activated complement C5b-9, and inflammation. Organ injury in seropositive CD59−/− rats was prevented
by a complement inhibitor. Significant pathological changes in seropositive CD59−/− rats were not seen in optic nerve,
spinal cord or brain, including circumventricular tissue. These results implicate a major protective role of CD59 outside of
the central nervous system in seropositive NMO, and hence offer an explanation as to why peripheral, AQP4-expressing
cells are largely unaffected in NMO.
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Complement-mediated cytotoxicity plays a central role
in the pathogenesis of seropositive neuromyelitis optica
spectrum disorders (herein called NMO), in which im-
munoglobulin G autoantibodies against water channel
aquaporin-4 (AQP4), called AQP4-IgG, bind to astro-
cytes in brain, spinal cord and optic nerve [9, 10]. Fol-
lowing astrocyte injury, downstream inflammation,
blood-brain barrier disruption and potentially additional
mechanisms result in oligodendrocyte injury and demye-
lination [11, 17, 29]. Optic neuritis and transverse myelitis
are the major clinical manifestations of NMO, which can
produce visual and motor impairment, and brain involve-
ment can occur as well. Though AQP4 is expressed in* Correspondence: Alan.Verkman@ucsf.edu; http://www.ucsf.edu/verklab
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(http://creativecommons.org/publicdomain/zesome peripheral organs outside of the central nervous
system, including skeletal muscle, kidney and stomach
[8, 19], these organs are rarely affected in NMO, with
only a few reports of NMO-associated myositis associ-
ated with elevated creatine phosphokinase and skeletal
muscle pathology [7, 13, 27].
It has been unclear why peripheral AQP4-expressing
cells, which are exposed to high levels of circulating
AQP4-IgG in seropositive NMO, are largely spared.
Rodent studies show prompt deposition of circulating
AQP4-IgG on peripheral AQP4-expressing cells [1, 20],
and humans can be AQP4-IgG seropositive for many years
prior to clinical manifestations of NMO [16]. Rodents ad-
ministered AQP4-IgG systemically do not spontaneously
develop pathological changes in the central nervous
system or in peripheral organs, though pathology inle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
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blood-brain barrier [1].
Here, we tested the hypothesis that complement regu-
lator protein CD59 is responsible for protection of
AQP4-expressing peripheral cells in seropositive NMO.
CD59 is a phosphoinositol-linked membrane glycoprotein
that inhibits formation of the complement terminal mem-
brane attack complex [6, 21, 26, 34]. The motivation for
this work is the expression of CD59 in AQP4-expressing
cells in the central nervous system and in the periphery,
and our prior data showing that CD59−/− mice are highly
sensitive to development of NMO pathology following dir-
ect administration of AQP4-IgG and human complement
into brain or cerebrospinal fluid [33]. CD59−/− rats also
develop marked brain and spinal cord pathology following
direct AQP4-IgG administration [32], albeit without the
need for coadministration of complement, because rats,
unlike mice, have an active classical complement system
[2, 22]. We report here marked injury to skeletal muscle
following systemic AQP4-IgG administration to CD59−/−
rats, offering an explanation for the sparing of peripheral
organs in seropositive NMO.Materials and methods
Materials
Purified recombinant AQP4-IgG (rAb-53) [3, 5] was
provided by Dr. Jeffrey Bennett (Univ. Colorado, Denver)
and (non-NMO) pooled human IgG, as control, was
purchased from Pierce Biotechnology (Rockford, IL).
Some studies were done using an antibody fragment-
based complement inhibitor, herein called Compinh (to
be reported separately), which inhibits serum complement
activity by >95% for 8–12 h after intravenous administra-
tion. Unless otherwise specified chemicals were purchased
from Sigma-Aldrich (St. Louis, MO).
CD59−/− rats
CD59−/− rats in a Sprague-Dawley background were
custom-generated by Transposagen Biopharm. Inc.
(Lexingtobon, KY) using CRISPR-Cas9 gene targeting
technology as described [32]. In vivo studies were
done on 8- to 10-week-old, weight-matched CD59+/+
and CD59−/− rats. Rats were maintained in air-filtered
cages and fed normal rat chow in the University of
California, San Francisco (UCSF) Animal Care facility.
All procedures were approved by the UCSF Committee on
Animal Research (approval number AN108551).
Blood and urine analysis
Blood (800 μL) was collected before and 24 h after
AQP4-IgG injection. Hematological parameters were
measured using a Genesis Hematology Analyzer (Oxford
Science, Oxford, CT) in which 80 μL blood was collectedinto a MiniCollect tube with EDTA (Greiner Bio-One
GmbH, Kremsmunster, Austria). Serum was obtained
by collection of blood in 1.5-ml Eppendoff tubes then
allowing clotting for 30 min followed by centrifugation
at 800 g for 10 min at 4 °C. Serum was frozen at −70 °
C for blood chemistry analyses (IDEXX BioResearch,
Sacramento, CA). Urine was collected for determin-
ation of osmolality using a freezing-point depression
osmometer (Model 3320 Osmometer, Advanced Instru-
ments Inc., Natick, MA).
AQP4-IgG pharmacokinetics
Adult CD59+/+ and CD59−/− rats were administered
AQP4-IgG (4 mg/kg body weight in PBS) by intraperito-
neal injection in a total volume of 500 μL. Blood was
collected through the tail vein at 1, 2, 4, 6, 8, 24 and
48 h, left for 30 min at room temperature to allow clot-
ting, and centrifuged for 10 min at 800 g at 4 °C. Serum
was diluted 50,000-fold and human IgG concentration
was determined using a human IgG ELISA kit (GenWay,
San Diego, CA).
Intraperitoneal injection model
AQP4-IgG or (non-NMO) control human IgG (5 mg/kg
body weight) was injected intraperitoneally. At 24 h,
clinical motor scores were recorded, as adapted from
scoring used for neuroinflammation models in rodents
[18]: score 0, normal movement; score 1, tail paralysis;
score 2, hindlimb paralysis; score 3, hindlimb and fron-
tlimb paresis with breathing difficulty; score 4, complete
paralysis with moribund condition. Then rats were
deeply anesthetized using ketamine (100 mg/kg) and
xylazine (10 mg/kg) and transcardially perfused with
200 mL heparinized PBS and 200 mL of 4% PFA in PBS.
Brain, optic nerve, spinal cord (cervical), skeletal muscle,
kidney and stomach were removed and post-fixed for
4 h in 4% paraformaldehyde (PFA) and cryoprotected in
20% sucrose. Tissues were embedding in OCT com-
pound and sectioned at 7-μm thickness using a cryostat
(CM1900, Leica) for immunofluorescence. For comple-
ment inhibition studies, Compinh (50 mg/kg) was injected
intravenously just before and 12 h after intraperitoneal
AQP4-IgG (or control IgG) administration.
Immunofluorescence
Frozen sections of harvested tissues were immunostained
as described [32]. Briefly, sections were incubated in
blocking solution (1% BSA containing 0.3% Triton X-100
in PBS) for 1 h at room temperature, then incubated over-
night at 4 °C with primary antibodies against AQP4
(1:200, Santa Cruz Biotechnology), human IgG (1:200,
Santa Cruz Biotechnology), C5b-9 (1:100, Hycult Biotech,
PA), CD45 (1:50, Cambridge, MA), CD59 and CD55 (1:50,
LSBio, Seattle, WA), CD46 (1:50, Abcam, MA), GFAP
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ecule 1 (Iba1; 1:400, Wako, Richmond, VA), or myelin
basic protein (MBP, 1:100, Santa Cruz Biotechnology),
followed by the appropriate species-specific Alexa Fluor-
conjugated secondary antibody for 1 h (5 μg/mL each,
Invitrogen) at room temperature. Sections were mounted
with Prolong Gold antifade reagent with DAPI (Invitrogen,
Life Technologies, Eugene, OR) for visualization of im-
munofluorescence on a Leica fluorescence microscope or
Nikon confocal microscope.Statistics
Data are presented as mean ± S.E.M. Statistical analysis
was performed using Prism 5 GraphPad Software pack-
age (San Diego, CA). The normality of the data was
established by Bartlett’s test for equal variances and a
one-way ANOVA with Newmann-Keuls post-hoc test to
compare groups.AQP4 CDAQP4 GFAP MBP
CD59+/+
CD59-/-
brain
skeletal
muscle
kidney
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Fig. 1 Expression of AQP4 and complement regulator proteins CD59, CD55
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Expression of complement inhibitor proteins in
AQP4-expressing organs
Immunofluorescence of AQP4 and complement inhibitor
proteins in Fig. 1a shows coexpression of AQP4 and CD59
in three major peripheral tissues in which AQP4 is
expressed – skeletal muscle, kidney and stomach. Staining
was seen in sarcolemma in skeletal muscle, in basolateral
plasma membrane in inner medullary collecting duct in
kidney, and in parietal cells in glands in stomach. CD59
immunofluorescence was absent in organs from CD59−/−
rats, and AQP4 immunofluorescence did not differ signifi-
cantly in tissues from CD59+/+ and CD59−/− rats (relative
to 1.0 for CD59+/+ rats: 1.01 ± 0.07 (skeletal muscle);
1.04 ± 0.07 (kidney); 0.96 ± 0.09 (stomach)). Complement
inhibitor protein CD46 was seen in stomach > kidney >
skeletal muscle, with similar expression in CD59+/+ and
CD59−/− rats. Relatively little CD55 was seen in these
peripheral organs.CD55CD4659
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Fig. 2 Marked weakness and CK elevation in CD59−/− rats following
systemic AQP4-IgG administration. a AQP4-IgG pharmacokinetics in
CD59+/+ and CD59−/− rats (mean ± S.E.M., 3 rats per genotype).
b Clinical motor score at 24 h following IP injection of AQP4-IgG.
Data shown for individual rats along with mean ± S.E.M. c Serum CK
for indicated groups (mean ± S.E.M., 6 rats per genotype, except 4
rats for Compinh-treated group, **P < 0.01 comparing to AQP4-IgG-
treated AQP4+/+ rats)
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brain showed gross colocalization of astrocyte markers
AQP4 and GFAP, with a distinct pattern of myelin
(MBP) expression (Fig. 1b–d, left 3 panels). AQP4 coex-
pression with CD59 was seen in the three CNS tissues,
with strongest CD59 immunofluorescence in brain, with
different levels of CD46 and CD55 seen in the various
tissues (right 4 panels). AQP4 immunofluorescence did not
differ significantly in tissues from CD59+/+ and CD59−/−
rats (relative to 1.0 for CD59+/+ rats: 1.01 ± 0.06 (optic
nerve); 0.97 ± 0.04 (spinal cord); 0.96 ± 0.09 (brain)). CD59
immunofluorescence was absent in CNS tissues from
CD59−/− rats, and CD46 and CD55 immunofluorescence
was similar in CD59+/+ and CD59−/− rats.
Marked weakness and serum CK elevation in CD59−/− rats
following systemic AQP4-IgG administration
AQP4-IgG pharmacokinetics in CD59+/+ and CD59−/−
rats was measured following a single intraperitoneal in-
jection of AQP4-IgG. Human IgG concentration in rat
serum was assayed by ELISA against human IgG, which
does not detect rat IgG. Fig. 2a shows human IgG concen-
tration in rat serum over 48 h. AQP4-IgG concentration
increased over the first few hours as it was absorbed from
the peritoneal cavity, was maximum at ~6 h, and then de-
creased with t1/2 ~ 48 h. Slightly lower AQP4-IgG concen-
trations were seen in CD59−/− compared to CD59+/+ rats.
All AQP4-IgG-treated CD59−/− rats developed marked
weakness and motor disability at 24 h, as exemplified in
the short clip in Additional file 1 Video S1, with motor
score data summarized in Fig. 2b. Little or no motor dis-
ability was seen in AQP4-IgG-treated CD59+/+ rats, in
control (non-NMO) human IgG-treated CD59+/+ and
CD59−/− rats, and in AQP4-IgG-treated CD59−/− rats
administered a complement inhibitor just before and
12 h after AQP4-IgG administration. There was remark-
able, >900-fold elevation in serum CK in the AQP4-IgG
treated CD59−/− rats, which was largely prevented by
complement inhibition (Fig. 2c). Though there are sev-
eral potential sources of CK, the exceptionally high
levels found in the treated rats are very likely to come
from skeletal muscle.
Tables 1 and 2 summarize hematological parameters
and chemistries of control and AQP4-IgG-treated rats.
The data indicate a mild hemolytic anemia in untreated
CD59−/− rats as evidenced by reduced hematocrit and
mild reticulocytosis, as has been reported in humans
lacking CD59 [4, 15]. In AQP4-IgG-treated CD59−/−
rats, in addition to the marked elevation in CK, changes
were seen in liver enzymes (AST and ALT) and kidney
indices (BUN and creatinine), which is likely due to sec-
ondary effects of muscle injury, rhabdomyolysis and dehy-
dration with reduced food intake. The treated CD59−/−
rats also manifested a urinary concentrating defect (urineosmolality: AQP4-IgG-treated 521 ± 96 mOsm vs. control
IgG-treated 1413 ± 155 mOsm, S.E.M. 6 rats per group).
The hemoconcentration in CD59−/− rats is likely due to
reduced fluid intake and dehydration.
Pathology in peripheral, AQP4-expressing organs in
AQP4-IgG seropositive CD59−/− rats
AQP4 and myosin-II immunofluorescence in hindlimb
(tibialis anterior) muscle showed marked injury in
AQP4-IgG treated CD59−/− rats, with vacuole formation
and disorganized myofibrils (Fig. 3a). Little or no ab-
normalities were seen in control (non-NMO) human
IgG-treated CD59+/+ rats, AQP4-IgG-treated CD59+/+ rats,
or complement inhibitor / AQP4-IgG-treated CD59−/− rats.
Table 1 Hematological parameters before and 24 h after IP injection of AQP4-IgG in CD59−/− and CD59+/+ rats
Hb (g/dl) RBC (1012/L) HCT (%) RDW (%) Retic (%) WBC (109/L) Plt (109/L)
Before AQP4-IgG administration
CD59+/+ 15.1 ± 2.0 9.2 ± 1.2 44.4 ± 6.0 13.5 ± 1.9 0.0 ± 0.0 7.5 ± 0.7 870 ± 162
CD59−/− 13.9 ± 1.1 8.5 ± 0.9 41.5 ± 4.4 13.4 ± 1.0 0.4 ± 0.2+ 8.1 ± 1.4 828 ± 114
24 h after AQP4-IgG administration
CD59+/+ 13.6 ± 1.1 8.8 ± 0.9 40.8 ± 3.0 13.3 ± 1.9 0.0 ± 0.0 6.8 ± 3.4 741 ± 207
CD59−/− 18.4 ± 1.8* 11.4 ± 1.9* 55.7 ± 6.1* 13.6 ± 0.9 0.3 ± 0.1+ 9.1 ± 5.6 685 ± 195
CD59−/− + Compinh 13.4 ± 0.5 7.6 ± 0.2 40.0 ± 2.4 12.6 ± 0.7 0.3 ± 0.2
+ 5.2 ± 1.2 686 ± 99
Mean ± S.E.M. of 4–6 rats per genotype (three males and three females)
Hb hemoglobin, RBC red blood cell count, HCT hematocrit, RDW RBC distribution width; Retic reticulocyte count, WBC white blood cell count, Plts platelet count
*p < 0.01 comparing with AQP4-IgG-treated CD59+/+ rats. + p < 0.01 comparing with untreated CD59+/+ rats
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pattern and was significantly reduced in skeletal muscle of
AQP4-IgG-treated CD59−/− rats, with quantitative data
summarized in Fig. 3b. Similar pathology was seen in skel-
etal muscle from forelimb (triceps brachii), back (latissimus
dorsi) and diaphragm (Fig. 3c). Fig. 3d shows deposition of
activated complement (C5b-9) and inflammatory cell infil-
tration (CD45) in tibialis anterior muscle of AQP4-IgG-
treated CD59−/− rats. We did not stain for leukocyte sub-
types. AQP4-IgG deposition (hIgG staining) was seen in
the AQP4-IgG-treated CD59+/+ rats, but to a lesser extent
in CD59−/− rats where AQP4 was largely gone. CD59 thusTable 2 Blood chemistries before and 24 h after IP injection of AQP
Parameters CD59+/+
before
CD59+/+
after
ALP (U/L) 106 ± 77 63 ± 60
AST (U/L) 60 ± 9 81 ± 23
ALT (U/L) 36 ± 9 30 ± 9
Creatine Kinase (U/L) 85 ± 9 120 ± 51
Albumin (g/dL) 2.9 ± 0.2 2.9 ± 0.3
Total Bilirubin (mg/dL) 0.1 ± 0.1 0.1 ± 0.0
Total Protein (g/dL) 5.8 ± 0.3 6.1 ± 0.3
Globulin (g/dL) 2.9 ± 0.4 3.2 ± 0.4
BUN (mg/dL) 13.6 ± 2.9 13.3 ± 3.3
Creatinine (mg/dL) 0.2 ± 0.0 0.3 ± 0.1
Cholesterol (mg/dL) 84 ± 20 83 ± 21
Glucose (mg/dL) 208 ± 32 183 ± 14
Calcium (mg/dL) 6.9 ± 4.4 5.1 ± 4.9
Phosphorus (mg/dL) 5.3 ± 0.8 6.1 ± 1.1
Bicarbonate (mmol/L) 20 ± 4 21 ± 2
Chloride (mmol/L) 99 ± 4 98 ± 5
Sodium (mmol/L) 136 ± 8 140 ± 2
Mean ± S.E.M. of 4–6 rats per genotype (three males and three females)
ALP alkaline phosphatase, AST/ALT aspartate aminotransferase/alanine aminotransfe
*p < 0.01 comparing with untreated CD59−/− ratsplays an important role in protection of skeletal muscle in
seropositive NMO.
In kidney inner medulla where AQP4-expressing inner
medullary collecting ducts are located, AQP4-IgG-treated
rats showed loss of AQP4 immunofluorescence, as well as
some deposition of activated complement and inflamma-
tory cell infiltration, each of which were prevented by
complement inhibition (Fig. 4a). Interestingly, in stomach,
no significant changes in AQP4 expression were seen in
AQP4-IgG-treated CD59−/− rats, nor was there demon-
strable deposition of activated complement or inflamma-
tory cell infiltration (Fig. 4b).4-IgG in CD59−/− and CD59+/+ rats
CD59−/−
before
CD59−/−
after
CD59−/−
+Compinh
142 ± 93 117 ± 89 122 ± 21
129 ± 51 5784 ± 1021* 252 ± 34*
50 ± 10 1182 ± 298* 60 ± 14
92 ± 9 106,767 ± 42901* 547 ± 84*
2.9 ± 0.2 2.9 ± 0.3 2.8 ± 0.3
0.1 ± 0.0 0.2 ± 0.1 0.1 ± 0.0
5.8 ± 0.3 6.7 ± 0.6 5.6 ± 0.3
2.9 ± 0.2 3.8 ± 0.1 2.8 ± 0.1
14.7 ± 1.3 124 ± 46* 16.0 ± 4.4
0.2 ± 0.1 1.2 ± 0.8* 0.3 ± 0.1
69 ± 11 110 ± 25 71 ± 10
198 ± 39 148 ± 82 205 ± 12
7.1 ± 4.2 6.2 ± 3.9 9.9 ± 0.2
6.0 ± 0.9 16.7 ± 6.1 6.9 ± 0.7
21 ± 2 20 ± 4 22 ± 2
100 ± 3 90 ± 5 105 ± 3
138 ± 5 136 ± 6 143 ± 3
rase, CK creatine kinase, BUN blood urea nitrogen
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Fig. 3 Immunofluorescence in skeletal muscle at 24 h after intraperitoneal AQP4-IgG administration. a AQP4 and myosin-II immunofluorescence
of tibialis anterior muscle, representative of 4–6 rats per group. b Relative AQP4 immunofluorescence (mean ± S.E.M., 4–6 rats per group, ** P < 0.01
compared to control IgG group). c Immunofluorescence of front limb (triceps brachii), back (latissimus dorsi) and diaphragm muscle in
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tibialis anterior muscle. Representative of 3 rats per group
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AQP4-IgG seropositive CD59−/− rats
Examination of optic nerve (Fig. 5a), spinal cord (Fig. 5b)
and circumventricular brain (Fig. 5c) did not show NMO
pathology in AQP4-IgG-treated CD59−/− rats. AQP4 ex-
pression was similar to that in control CD59+/+ rats, and
neither complement deposition nor inflammation (CD45
and Iba-1) was seen. AQP4-IgG deposition (hIgG) was notseen in optic nerve or spinal cord, suggesting that AQP4-
IgG cannot access these tissues over the 24-h time. hIgG
staining was, however, mildly positive in circumventricular
brain tissue that lacks a tight blood-brain barrier.
Discussion
The principal finding here is that rats lacking comple-
ment inhibitor protein CD59 develop marked weakness
hIgG C5b-9AQP4 CD45
stomach
hIgG C5b-9AQP4
kidney
CD59+/+
control IgG
CD59-/-
AQP4-IgG
CD59+/+
AQP4-IgG
CD45
CD59-/-
AQP4-IgG
+Compinh
CD59+/+
control IgG
CD59-/-
AQP4-IgG
CD59+/+
AQP4-IgG
100 µm
100 µm
5 µm
Fig. 4 Immunofluorescence in kidney and stomach at 24 h after
intraperitoneal AQP4-IgG administration. AQP4, hIgG, C5b-9 and CD45
immunofluorescence in kidney (a) and stomach (b). Representative of
3 rats per group
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muscle following systemic administration of AQP4-IgG,
whereas under identical conditions wildtype rats do not.
Mild pathological changes were also seen in AQP4-
expressing epithelial cells in the renal inner medullary
collecting duct, but not in AQP4-expressing gastric
parietal cells. Injured AQP4-expressing cells in skeletal
muscle of CD59−/− rats showed reduced AQP4 expres-
sion, deposition of activated complement, and inflam-
mation. Skeletal muscle injury was associated with
marked elevation in serum creatine phosphokinase,
which was largely prevented by complement inhibition,
supporting the conclusion that complement-dependent
cytotoxicity is responsible for peripheral organ injury in
the seropositive CD59−/− rats. The absence of demonstrable
brain or spinal cord injury suggests that the marked motor
dysfunction seen by 24 h is the consequence of acute skel-
etal muscle injury rather than central nervous system injury.
Respiratory failure because of diaphragmatic involvement
may have contributed to the early mortality. The study here
required CD59−/− rats rather than mice because of the lowactivity of mouse complement, precluding the use of
mice to study the consequences of systemic AQP4-IgG
seropositivity.
There are a few reports of NMO myositis with ele-
vated serum CK, though no reports of NMO-associated
pathology in other AQP4-expressing peripheral organs.
In a report of 2 seropositive NMO patients with diffuse
myalgias, a substantial transient elevation of CK was
found, with muscle biopsy showing reduced AQP4 ex-
pression and deposition of activated complement [13],
similar to the pathological changes seen in seropositive
CD59−/− rats here. One case of CK elevation at the time
of NMO attacks was reported, but without muscle find-
ings [7]. In a retrospective study of 733 cases of NMO in
Japan, three patients were found with CK elevation and
general fatigue weeks before symptoms of optic neuritis
[27]. Though renal disease has not been reported in
NMO, perhaps some patients manifest a mild urinary
concentrating defect, as found in AQP4 knockout mice
[12], and perhaps urinalysis might reveal cellular evidence
of collecting duct injury.
Our findings support the conclusion that peripheral
organ injury is largely absent in seropositive NMO be-
cause of protection by CD59 against complement-
mediated injury in AQP4-expressing cells. Perhaps the
myositis seen in a very small number of NMO patients
is caused by altered CD59 expression or CD59 polymor-
phisms, though this possibility has not been investigated.
It would also be interesting to study the expression of
CD59 and other complement regulator proteins in cen-
tral nervous system and peripheral organ in human
NMO. The apparent greater sensitivity of skeletal muscle
to complement-induced injury, compared with other
AQP4-expressing peripheral organs, might be related to
the greater metabolic activity of skeletal muscle cells, or
perhaps to differences in the expression of other com-
plement inhibitors. Our results also support the central
role of CD59 in the modulation of AQP4-IgG-initiated
complement injury and hence suggest the potential
therapeutic benefit in NMO of upregulation of astrocyte
CD59 or alternative complement regulator proteins by
pharmacological or other means.
Previously, various explanations have been offered for
the general absence of NMO disease in peripheral,
AQP4-expressing organs. Once set of explanations focus
on AQP4, postulating that differences in AQP4 expres-
sion, localization or membrane clustering affect AQP4-
IgG binding and consequent complement activation
[14, 25]. However, the robust binding of AQP4-IgG to
peripheral AQP4-expressing cells in rodents argues strongly
against an AQP4-centric explanation, as do AQP4 bio-
chemical and freeze-fracture electron microscopy studies
[19, 23, 30, 31]. AQP4-IgG is deposited in skeletal
muscle where it has been studied in seropositive humans
brain
Iba-1AQP4 C5b-9 CD45AQP4 hIgG
optic nerve
spinal cord
hIgG C5b-9AQP4 CD45AQP4 Iba-1
0.5 mm 50 µm
hIgG C5b-9AQP4 CD45 Iba-1AQP4
CD59+/+
control IgG
CD59+/+
AQP4-IgG
CD59-/-
AQP4-IgG
CD59+/+
control IgG
CD59+/+
AQP4-IgG
CD59-/-
AQP4-IgG
CD59+/+
control IgG
CD59+/+
AQP4-IgG
CD59-/-
AQP4-IgG
GFAP
100 µm 50 µm
0.5 mm 50 µm
GFAP
GFAP
Fig. 5 Immunofluorescence in optic nerve, spinal cord, and brain at 24 h after intraperitoneal AQP4-IgG administration. AQP4 (low and high
magnification of boxed area), GFAP, hIgG, C5b-9, CD45 and Iba-1 immunofluoresence of optic nerve (a), spinal cord (b) and periventricular
brain (c). Representative of 3 rats per group
Yao and Verkman Acta Neuropathologica Communications  (2017) 5:57 Page 8 of 10[13], and AQP4-IgG is rapidly deposited in multiple
AQP4-expressing peripheral organs following its systemic
delivery to rodents [1, 20]. Another possible explanation
for sparing of peripheral organs in NMO is the unique mi-
lieu of the central nervous system, which, unlike periph-
eral organs, might amplify an inflammatory response
because of the presence of microglia, a narrow extracellular
space, and a blood-brain barrier that impedes inflammatory
cell exit. However, there is no experimental evidence to
support this explanation.
The findings here raise the question of why CD59 in as-
trocytes does not fully protect against AQP4-IgG/comple-
ment injury as it appears to do in peripheral organs. Ourprior data using mouse and rat models of NMO produced
by injection of AQP4-IgG into brain or the spinal cerebro-
spinal space implicate a protective role for CD59 in brain
and spinal cord in vivo [32, 33], which was supported by
in vitro data in astrocyte cultures from knockout mice and
rats or following CD59 enzymatic neutralization. Saadoun
and Papadopoulos [24] reported that complement inhibi-
tors, including CD59, are not protective against comple-
ment injury in CNS tissues. Though this conclusion is not
supported by our findings in CD59−/− rats and mice, they
reported interesting immunofluorescence in mouse brain
in which CD59 expression was seen on astrocyte cell bodies
but not on AQP4-rich foot-processes near microvessels.
Yao and Verkman Acta Neuropathologica Communications  (2017) 5:57 Page 9 of 10We believe that higher-resolution imaging studies using
electron microscopy or super-resolution fluorescence mi-
croscopy are needed to resolve unambiguously the subcel-
lular localization of CD59 and AQP4 in brain sections.
With regard to why CD59 is not fully protective against
AQP4-IgG injury in the central nervous system, perhaps, as
mentioned above, the unique cellular and physical milieu in
brain, spinal cord and optic nerve, such as the presence of
microglia and a narrow extracellular space, might amplify
subthreshold AQP4-IgG-induced injury. We recently re-
ported evidence for complement bystander injury to oligo-
dendrocytes, which lack CD59, following exposure of
nearby astrocytes to AQP4-IgG and complement [28].
While bystander cytotoxicity may be a major mechanism of
cellular injury in the central nervous system, it may be in-
consequential in peripheral AQP4-expressing organs.
Lastly, we acknowledge limitations in extrapolating the
conclusions here from studies done in CD59−/− rats to hu-
man NMO. Though the major anatomical structures are
similar in rats and humans, there are differences in the ra-
tios of various cell types in the central nervous system
such as astrocytes and neurons, and there may be differ-
ences in expression levels of CD59 and other complement
inhibitor proteins. Though there is compelling evidence
for the pathogenicity of AQP4-IgG and complement, the
passive-transfer model used here may not fully recapitu-
late the pathogenesis of seropositive NMO in humans,
where additional mechanisms, perhaps cytotoxic T cells,
might also contribute. Finally, the data here were from
short-term follow-up after systemic AQP4-IgG adminis-
tration to rats, which was necessitated by the severe path-
ology in AQP4-IgG-treated CD59−/− rats. Peripheral
organs in humans with seropositive NMO can be exposed
to AQP4-IgG continuously for many years or decades.
Notwithstanding these potential limitations, our results
offer a logical explanation for the general absence of
NMO disease outside of the central nervous system.
Conclusions
Our results provide evidence that CD59 expression in per-
ipheral, AQP4-expressing organs is responsible for the ab-
sence of peripheral organ injury in seropositive NMO.
Additional file
Additional file 1: Video S1. AQP4+/+ rat (right) and AQP4−/− rat (left) at
24 h after intraperitoneal AQP4-IgG administration. (MOV 2356 kb)
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